ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

207
Analysis
Health Care • China
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
bullish•Alibaba
•15 Jan 2020 10:06

Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do

2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...

Logo
722 Views
Share
bullish•Alibaba
•08 Jan 2020 17:38

2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
788 Views
Share
bullish•Smartkarma
•12 Sep 2019 15:33

Hong Kong IPO Analytics - Regular Cornerstone Investors and Track Record

At the beginning of this year, we at Aequitas Research, wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
1.1k Views
Share
•05 Aug 2019 11:11

HK IPO Analytics 1H2019: MS and CICC Stand Out

At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
794 Views
Share
bearish•Cross Asset Strategy
•28 Jul 2019 13:24

🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma

TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today.  The weight of...

Logo
722 Views
Share
x